肿瘤细胞治疗研究
FRONTIER PAPERS
Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression
分析了 44 个队列（2 个一线队列和 42 个复发/难治性队列）的 52 篇报告，共纳入 1833 例患者。
Slowing Mortality Improvements in Multiple Myeloma Despite Novel Therapies: Global Disparities by Sociodemographic Index, 1990-2023.
方法 发病率和死亡率数据提取自Global Burden of Disease 2023 Results Tool，包括95%不确定性区间。
Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myeloma.
本综述整合了近期3期试验的证据，为临床医生提供了MM个性化、风险适应管理的更新框架。
Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and
共纳入 26 项研究，包含 2,246 例患者。
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
多发性骨髓瘤 (MM) 的治疗干预领域已取得重大进展，导致其临床管理发生变革性转变。
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and r
这项回顾性分析证实，澳大利亚RRMM患者的结局一致较差。仍然迫切需要提高CAR-T等新型治疗在临床试验之外的可及性。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
